603882 金域医学
已收盘 09-30 15:00:00
资讯
新帖
简况
金域医学(603882)披露股份回购实施结果暨股份变动公告,9月30日股价上涨2.87%
证券之星 · 09-30 22:15
金域医学(603882)披露股份回购实施结果暨股份变动公告,9月30日股价上涨2.87%
股市必读:金域医学(603882)9月24日董秘有最新回复
证券之星 · 09-28
股市必读:金域医学(603882)9月24日董秘有最新回复
金域医学:感染探针捕获、肿瘤多基因检测、全外显子检测等同比分别实现10%~40%增长
证券之星 · 09-24
金域医学:感染探针捕获、肿瘤多基因检测、全外显子检测等同比分别实现10%~40%增长
金域医学:2026年半年度实验室综合人效同比提升15.9%
证券之星 · 09-24
金域医学:2026年半年度实验室综合人效同比提升15.9%
金域医学涨6.06%,国金证券二周前给出“买入”评级
证券之星 · 09-14
金域医学涨6.06%,国金证券二周前给出“买入”评级
每周股票复盘:金域医学(603882)将召开2026年半年度业绩说明会
证券之星 · 09-13
每周股票复盘:金域医学(603882)将召开2026年半年度业绩说明会
金域医学获得发明专利授权:“基因突变分析、查询序列建立方法、系统、设备及介质”
证券之星 · 09-11
金域医学获得发明专利授权:“基因突变分析、查询序列建立方法、系统、设备及介质”
金域医学(603882)披露将召开2026年半年度业绩说明会,9月9日股价上涨0.49%
证券之星 · 09-09
金域医学(603882)披露将召开2026年半年度业绩说明会,9月9日股价上涨0.49%
金域医学新注册《区域检验质控系统V1.0》等2个项目的软件著作权
证券之星 · 09-08
金域医学新注册《区域检验质控系统V1.0》等2个项目的软件著作权
每周股票复盘:金域医学(603882)股东拟减持不超1%股份
证券之星 · 09-06
每周股票复盘:金域医学(603882)股东拟减持不超1%股份
金域医学新注册《金域学术资源运营看板系统APPV1.0》项目的软件著作权
证券之星 · 09-05
金域医学新注册《金域学术资源运营看板系统APPV1.0》项目的软件著作权
股市必读:金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》
证券之星 · 09-03
股市必读:金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》
股市必读:金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》
证券之星 · 09-02
股市必读:金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》
金域医学(603882.SH):国创开元拟减持不超1%股份
智通财经 · 09-01
金域医学(603882.SH):国创开元拟减持不超1%股份
国金证券:给予金域医学买入评级
证券之星 · 08-26
国金证券:给予金域医学买入评级
金域医学(603882)2026年中报简析:净利润同比增长324.27%,盈利能力上升
证券之星 · 08-26
金域医学(603882)2026年中报简析:净利润同比增长324.27%,盈利能力上升
金域医学(603882)披露2026年半年度报告,8月25日股价下跌1.45%
证券之星 · 08-25
金域医学(603882)披露2026年半年度报告,8月25日股价下跌1.45%
金域医学(603882)6月30日股东户数3.97万户,较上期减少7.89%
证券之星 · 08-25
金域医学(603882)6月30日股东户数3.97万户,较上期减少7.89%
金域医学2026年半年报:降本增效显效,业绩实现扭亏为盈
蓝鲸财经 · 08-25
金域医学2026年半年报:降本增效显效,业绩实现扭亏为盈
图解金域医学中报:第二季度单季净利润同比增长358.50%
证券之星 · 08-25
图解金域医学中报:第二季度单季净利润同比增长358.50%
加载更多
公司概况
公司名称:
广州金域医学检验集团股份有限公司
所属行业:
卫生
上市日期:
2017-09-08
主营业务:
广州金域医学检验集团股份有限公司的主营业务是第三方医学检验及病理诊断业务。公司的主要产品是医学诊断服务、销售诊断产品、健康体检业务、冷链物流服务。公司成功入选国家工业和信息化部公布的第七批产业技术基础公共服务平台名单,成为本次获批单位中唯一一家第三方医检机构,标志着公司的综合实力获得国家权威认可。
发行价格:
6.93
{"stockData":{"symbol":"603882","market":"SH","secType":"STK","nameCN":"金域医学","latestPrice":29.06,"timestamp":1790751600000,"preClose":28.25,"halted":0,"volume":12054017,"delay":0,"changeRate":0.0287,"floatShares":458000000,"shares":463000000,"eps":0.2197,"marketStatus":"已收盘","change":0.81,"latestTime":"09-30 15:00:00","open":28.2,"high":29.8,"low":27.88,"amount":350000000,"amplitude":0.068,"askPrice":29.07,"askSize":9,"bidPrice":29.06,"bidSize":59,"shortable":0,"etf":0,"ttmEps":0.2197,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":28.25,"symbolType":"stock","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":31.08,"lowLimit":25.43,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":463258275,"isCdr":false,"pbRate":2.13,"roa":"--","peRate":132.271279,"roe":"2.92%","epsLYR":-0.37,"committee":0.592262,"marketValue":13462000000,"turnoverRate":0.0263,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-10-08。","floatMarketCap":13310000000},"requestUrl":"/m/hq/s/603882","defaultTab":"news","newsList":[{"id":"2671788693","title":"金域医学(603882)披露股份回购实施结果暨股份变动公告,9月30日股价上涨2.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671788693","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671788693?lang=zh_cn&edition=full","pubTime":"2026-09-30 22:15","pubTimestamp":1790777721,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘,金域医学报收于29.06元,较前一交易日上涨2.87%,最新总市值为134.62亿元。该股当日开盘28.2元,最高29.8元,最低27.88元,成交额达3.5亿元,换手率为2.63%。近日,广州金域医学检验集团股份有限公司披露《关于股份回购实施结果暨股份变动的公告》。回购完成后公司股份总数未发生变化,不影响股权分布及控制权稳定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000037953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","SG9999001069.SGD","BK0042","603882","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670401312","title":"股市必读:金域医学(603882)9月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2670401312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670401312?lang=zh_cn&edition=full","pubTime":"2026-09-28 02:56","pubTimestamp":1790535371,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘,金域医学报收于29.39元,上涨1.1%,换手率3.04%,成交量13.94万手,成交额4.13亿元。董秘最新回复投资者: 对比医学检验赛道行业同业来看,去年公司人员规模、人均营收均下降约8%。投资者: 董秘您好,半年报公布感染探针捕获、肿瘤多基因检测、全外显子检测等营收增长分别达32.5%、21.1%、19.7%。当日关注点交易信息汇总:9月24日主力资金净流入238.05万元,占总成交额0.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882","BK0042","BK0284","SG9999001069.SGD","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669612874","title":"金域医学:感染探针捕获、肿瘤多基因检测、全外显子检测等同比分别实现10%~40%增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2669612874","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669612874?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:18","pubTimestamp":1790245088,"startTime":"0","endTime":"0","summary":"投资者提问:董秘您好,半年报公布感染探针捕获、肿瘤多基因检测、全外显子检测等营收增长分别达32.5%、21.1%、19.7%。2026年上半年,公司实体肿瘤、神经免疫性疾病、血液疾病、感染性疾病等检测业务实现稳健发展。其中,感染探针捕获、肿瘤多基因检测、全外显子检测等同比分别实现10%~40%增长,高于其他常规产品,成为新的业务增长极。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400032080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0236","603882","SG9999001069.SGD","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669461253","title":"金域医学:2026年半年度实验室综合人效同比提升15.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461253","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669461253?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:15","pubTimestamp":1790244912,"startTime":"0","endTime":"0","summary":"公司积极通过降本增效及数智化转型,强化内部运营管理,深入推进精益运营,提升运营效率。随着各项经营改善措施持续落地,公司主营业务经营保持韧性,核心业务发展逐步企稳,经营效率进一步提升,2026年第二季度,公司营业收入同比增长0.19%,2026年半年度,公司实验室综合人效同比提升15.9%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400032021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0284","BK0042","BK0236","603882","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667365920","title":"金域医学涨6.06%,国金证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667365920","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667365920?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:35","pubTimestamp":1789374958,"startTime":"0","endTime":"0","summary":"今日金域医学涨6.06%,收盘报27.48元。2026年8月26日,国金证券研究员甘坛焕发布了对金域医学的研报《盈利能力修复,医数融合构筑新增长》,该研报对金域医学给出“买入”评级。研报中预计26-28年公司归母净利润为4.05/5.17/6.02亿元,分别同比增长NA、28、17%,EPS分别为0.87、1.12、1.30元,现价对应PE为34、26、23倍,维持“买入”评级。金域医学个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507179","title":"每周股票复盘:金域医学(603882)将召开2026年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507179","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507179?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:21","pubTimestamp":1789237271,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘,金域医学报收于25.91元,较上周的26.7元下跌2.96%。本周,金域医学9月7日盘中最高价报26.86元。金域医学当前最新总市值120.03亿元,在医疗服务板块市值排名17/51,在两市A股市值排名1532/5218。本周关注点公司公告汇总:金域医学将于2026年9月15日召开2026年半年度业绩说明会。公司公告汇总广州金域医学检验集团股份有限公司将于2026年9月15日15:30-17:00通过“全景路演”网站召开2026年半年度业绩说明会,以网络文字互动方式与投资者交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0284","SG9999001069.SGD","BK0042","603882","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666515590","title":"金域医学获得发明专利授权:“基因突变分析、查询序列建立方法、系统、设备及介质”","url":"https://stock-news.laohu8.com/highlight/detail?id=2666515590","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666515590?lang=zh_cn&edition=full","pubTime":"2026-09-11 03:52","pubTimestamp":1789069958,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示金域医学新获得一项发明专利授权,专利名为“基因突变分析、查询序列建立方法、系统、设备及介质”,专利申请号为CN202510684521.1,授权日为2026年9月8日。本发明能够减少测序的操作不当或样本污染影响查询序列的准确性。今年以来金域医学新获得专利授权9个,较去年同期增加了200%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100011109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0284","BK0042","BK0236","603882","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666811925","title":"金域医学(603882)披露将召开2026年半年度业绩说明会,9月9日股价上涨0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666811925","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666811925?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:41","pubTimestamp":1788946897,"startTime":"0","endTime":"0","summary":"截至2026年9月9日收盘,金域医学报收于26.64元,较前一交易日上涨0.49%,最新总市值为123.41亿元。该股当日开盘26.4元,最高26.86元,最低26.26元,成交额达1.4亿元,换手率为1.14%。广州金域医学检验集团股份有限公司于近日发布《关于参加2026广东上市公司投资者集体接待日暨召开2026年半年度业绩说明会的公告》。公告显示,公司将于2026年9月15日15:30-17:00通过“全景路演”网站召开2026年半年度业绩说明会,以网络文字互动方式与投资者交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900030302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0284","603882","BK0236","SG9999001069.SGD","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665944310","title":"金域医学新注册《区域检验质控系统V1.0》等2个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2665944310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665944310?lang=zh_cn&edition=full","pubTime":"2026-09-08 02:15","pubTimestamp":1788804916,"startTime":"0","endTime":"0","summary":"证券之星消息,近日金域医学(603882)新注册了2个项目的软件著作权,包括《区域检验质控系统V1.0》、《金域区域检验数据平台移动端V1.0.0》等。今年以来金域医学新注册软件著作权40个,较去年同期减少了42.86%。结合公司2026年中报财务数据,今年上半年公司在研发方面投入了1.57亿元,同比减2.3%。通过天眼查大数据分析,广州金域医学检验集团股份有限公司共对外投资了59家企业,参与招投标项目30次;财产线索方面有商标信息767条,专利信息226条,著作权信息199条;此外企业还拥有行政许可62个。数据来源:天眼查APP以上内容为证券之星据公开信息整理,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800000682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0284","603882","SG9999001069.SGD","BK0236","BK0042","159180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665652983","title":"每周股票复盘:金域医学(603882)股东拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2665652983","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665652983?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:25","pubTimestamp":1788632711,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,金域医学报收于26.7元,较上周的27.42元下跌2.63%。因基金存续期届满,国创开元拟通过集中竞价方式减持不超过4,632,582股,占公司总股本的1.00%。截至2026年8月31日,已累计回购713.38万股,占总股本1.54%,支付金额18,811.76万元,回购最高价30.59元/股,最低价23.36元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0236","SG9999001069.SGD","BK0284","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665565403","title":"金域医学新注册《金域学术资源运营看板系统APPV1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2665565403","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665565403?lang=zh_cn&edition=full","pubTime":"2026-09-05 02:20","pubTimestamp":1788546026,"startTime":"0","endTime":"0","summary":"证券之星消息,近日金域医学(603882)新注册了《金域学术资源运营看板系统APPV1.0》项目的软件著作权。今年以来金域医学新注册软件著作权38个,较去年同期减少了45.71%。结合公司2026年中报财务数据,今年上半年公司在研发方面投入了1.57亿元,同比减2.3%。通过天眼查大数据分析,广州金域医学检验集团股份有限公司共对外投资了59家企业,参与招投标项目30次;财产线索方面有商标信息767条,专利信息226条,著作权信息199条;此外企业还拥有行政许可62个。数据来源:天眼查APP以上内容为证券之星据公开信息整理,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090500000216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159180","BK0042","BK0236","SG9999001069.SGD","603882","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664453748","title":"股市必读:金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664453748","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664453748?lang=zh_cn&edition=full","pubTime":"2026-09-03 01:53","pubTimestamp":1788371592,"startTime":"0","endTime":"0","summary":"公司公告汇总广州金域医学检验集团股份有限公司股东国创开元股权投资基金减持股份计划公告广州金域医学检验集团股份有限公司股东国创开元股权投资基金持有公司30,880,905股,占总股本的6.67%,股份来源为公司首次公开发行前取得。因基金存续期届满,国创开元拟通过集中竞价方式减持不超过4,632,582股,占公司总股本的1.00%。截至2026年8月31日,已累计回购713.38万股,占总股本1.54%,支付金额18,811.76万元,回购最高价30.59元/股,最低价23.36元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","SG9999001069.SGD","BK0284","603882","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664863633","title":"股市必读:金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664863633","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664863633?lang=zh_cn&edition=full","pubTime":"2026-09-02 01:28","pubTimestamp":1788283691,"startTime":"0","endTime":"0","summary":"公司公告汇总:截至2026年8月31日,金域医学已回购713.38万股,支付金额18,811.76万元,占总股本1.54%。公司公告汇总广州金域医学检验集团股份有限公司股东国创开元股权投资基金减持股份计划公告广州金域医学检验集团股份有限公司股东国创开元股权投资基金持有公司30,880,905股,占总股本的6.67%,股份来源为公司首次公开发行前取得。因基金存续期届满,国创开元拟通过集中竞价方式减持不超过4,632,582股,占公司总股本的1.00%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200001885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0284","BK0042","BK0236","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664830027","title":"金域医学(603882.SH):国创开元拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2664830027","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664830027?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:06","pubTimestamp":1788257193,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金域医学(603882.SH)发布公告,因基金存续期届满,股东国创开元拟通过集中竞价方式减持所持有的公司股份不超过463.26万股,占公司总股本的1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","BK0236","SG9999001069.SGD","BK0284","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662765559","title":"国金证券:给予金域医学买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662765559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662765559?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:43","pubTimestamp":1787705002,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕近期对金域医学进行研究并发布了研究报告《盈利能力修复,医数融合构筑新增长》,给予金域医学买入评级。 金域医学 2026年8月24日,公司发布2026年半年度报告。最新盈利预测明细如下:该股最近90天内共有7家机构给出评级,买入评级5家,增持评级2家;过去90天内机构目标均价为36.62。本文数据来源于国金证券股份有限公司,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600014986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662570877","title":"金域医学(603882)2026年中报简析:净利润同比增长324.27%,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2662570877","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662570877?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:13","pubTimestamp":1787696001,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期金域医学发布2026年中报。截至本报告期末,公司营业总收入28.84亿元,同比下降3.76%,归母净利润1.9亿元,同比上升324.27%。本报告期金域医学盈利能力上升,毛利率同比增幅8.19%,净利率同比增幅327%。持有金域医学最多的基金为大成景恒混合A,目前规模为3.88亿元,最新净值3.5057,较上一交易日上涨1.77%,近一年上涨0.72%。本文数据来源于金域医学2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600009457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662973655","title":"金域医学(603882)披露2026年半年度报告,8月25日股价下跌1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662973655","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662973655?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:46","pubTimestamp":1787654814,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,金域医学报收于29.3元,较前一交易日下跌1.45%,最新总市值为135.73亿元。公司于近日披露《广州金域医学检验集团股份有限公司2026年半年度报告》。公告显示,截至报告期末,公司总资产为9,138,563,699.60元,归属于上市公司股东的净资产为6,314,304,429.52元,较上年度末分别减少4.85%和6.17%。经营活动产生的现金流量净额为242,620,468.80元,同比减少30.77%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500039702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0236","BK0042","603882","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662738310","title":"金域医学(603882)6月30日股东户数3.97万户,较上期减少7.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662738310","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662738310?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:38","pubTimestamp":1787650734,"startTime":"0","endTime":"0","summary":"证券之星消息,近日金域医学披露,截至2026年6月30日公司股东户数为3.97万户,较3月31日减少3401.0户,减幅为7.89%。在医疗服务行业个股中,金域医学股东户数低于行业平均水平,截至6月30日,医疗服务行业平均股东户数为4.77万户。从股价来看,2026年3月31日至2026年6月30日,金域医学区间跌幅为14.39%,在此期间股东户数减少3401.0户,减幅为7.89%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500036682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","603882","BK0284","BK0042","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662783837","title":"金域医学2026年半年报:降本增效显效,业绩实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2662783837","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662783837?lang=zh_cn&edition=full","pubTime":"2026-08-25 11:37","pubTimestamp":1787629056,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月25日讯,8月24日,金域医学 公布2026年中报,公司依托第三方医学检验与病理诊断核心业务,通过持续推进降本增效及数智化转型,有效消化前期阶段性不利因素,报告期业绩实现扭亏为盈;同时,毛利率显著提升,经营韧性增强,核心业务发展逐步企稳。财报数据显示,报告期公司实现营业收入28.84亿元,同比下降3.76%;归母净利润1.90亿元,同比扭亏为盈;扣非净利润2.03亿元,同比增长307.38%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787624576896228463","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0236","BK0042","603882","BK0284","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662220345","title":"图解金域医学中报:第二季度单季净利润同比增长358.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662220345","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662220345?lang=zh_cn&edition=full","pubTime":"2026-08-25 02:40","pubTimestamp":1787596802,"startTime":"0","endTime":"0","summary":"证券之星消息,金域医学2026年中报显示,上半年度公司主营收入28.84亿元,同比下降3.76%;归母净利润1.9亿元,同比上升324.27%;扣非净利润2.03亿元,同比上升307.38%;其中2026年第二季度,公司单季度主营收入15.33亿元,同比上升0.19%;单季度归母净利润1.47亿元,同比上升358.5%;单季度扣非净利润1.51亿元,同比上升355.34%;负债率29.42%,投资收益347.78万元,财务费用193.05万元,毛利率36.71%。财报数据概要请见下图:本文数据来源于金域医学2026年中报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500005559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790863287482,"stockEarnings":[{"period":"1week","weight":-0.0003},{"period":"1month","weight":0.0614},{"period":"3month","weight":0.2408},{"period":"6month","weight":0.1164},{"period":"1year","weight":0.0073},{"period":"ytd","weight":0.0535}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州金域医学检验集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"39725人(较上一季度减少7.89%)","perCapita":"11530股","listingDate":"2017-09-08","address":"广东省广州市海珠区国际生物岛螺旋三路10号","registeredCapital":"46325万元","survey":" 广州金域医学检验集团股份有限公司的主营业务是第三方医学检验及病理诊断业务。公司的主要产品是医学诊断服务、销售诊断产品、健康体检业务、冷链物流服务。公司成功入选国家工业和信息化部公布的第七批产业技术基础公共服务平台名单,成为本次获批单位中唯一一家第三方医检机构,标志着公司的综合实力获得国家权威认可。","listedPrice":6.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金域医学(603882)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金域医学(603882)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金域医学,603882,金域医学股票,金域医学股票老虎,金域医学股票老虎国际,金域医学行情,金域医学股票行情,金域医学股价,金域医学股市,金域医学股票价格,金域医学股票交易,金域医学股票购买,金域医学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金域医学(603882)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金域医学(603882)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}